(JREM) JPMorgan s (Ireland) ICAV - - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: IE00BF4G6Z54 • Global Emerging Markets Equity
JREM: Emerging Markets, Equities, ESG, Research, Index, ETF
JPMorgans Global Emerging Markets Research Enhanced Index Equity (ESG) UCITS ETF, listed on XETRA under the ticker JREM, offers a strategic avenue for investors seeking exposure to emerging markets with an ESG focus. As part of the JPMorgan Asset Management lineup, it leverages the firms extensive expertise, combining rigorous ESG criteria with a data-driven approach to identify high-quality companies poised for growth.
The ETF tracks the Morningstar EM TME NR USD Index, which employs a unique methodology to evaluate both financial health and ESG performance. This dual focus ensures that the portfolio is not only aligned with sustainability goals but also positioned to capture companies with strong fundamentals and lower ESG risks. Morningstars indexing methodology is well-regarded for its balance between risk-adjusted returns and ESG considerations.
With assets under management of approximately 1.25 billion EUR, this ETF benefits from a substantial scale, which can enhance liquidity and reduce trading costs. The absence of listed P/E, P/B, or P/S metrics underscores the funds focus on qualitative ESG factors and long-term growth potential over traditional valuation multiples.
Listing on XETRA in USD highlights its appeal to European investors seeking USD-denominated exposure without currency hedge, making it an attractive option for diversifying currency risk within a portfolio. The UCITS structure ensures compliance with European regulatory standards, providing a layer of investor protection and operational transparency.
Investors considering JREM should be aware of the inherent volatility in emerging markets, which, while offering growth opportunities, also come with higher risks. The funds ESG focus may lead to exclusion of certain sectors, potentially impacting sector-specific returns. As with any ETF, understanding the underlying index and its methodology is crucial for alignment with investment objectives.
Additional Sources for JREM ETF
JREM ETF Overview
Market Cap in USD | 1,360m |
Category | Global Emerging Markets Equity |
IPO / Inception | 2018-12-05 |
JREM ETF Ratings
Growth 5y | 38.3% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -13.5 |
Analysts | - |
Fair Price Momentum | 27.03 EUR |
Fair Price DCF | - |
JREM Dividends
No Dividends PaidJREM Growth Ratios
Growth Correlation 3m | 36.2% |
Growth Correlation 12m | 80.8% |
Growth Correlation 5y | 14.4% |
CAGR 5y | 8.51% |
CAGR/Max DD 5y | 0.30 |
Sharpe Ratio 12m | 0.62 |
Alpha | 2.15 |
Beta | 0.64 |
Volatility | 18.60% |
Current Volume | 24.8k |
Average Volume 20d | 6.4k |
As of March 13, 2025, the stock is trading at EUR 29.26 with a total of 24,843 shares traded.
Over the past week, the price has changed by -1.45%, over one month by -4.02%, over three months by -2.06% and over the past year by +8.65%.
Partly, yes. Based on ValueRay Analyses, JPMorgan s (Ireland) ICAV - (XETRA:JREM) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 38.26 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of JREM as of March 2025 is 27.03. This means that JREM is currently overvalued and has a potential downside of -7.62%.
JPMorgan s (Ireland) ICAV - has no consensus analysts rating.
According to ValueRays Forecast Model, JREM JPMorgan s (Ireland) ICAV - will be worth about 30 in March 2026. The stock is currently trading at 29.26. This means that the stock has a potential upside of +2.39%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 30 | 2.4% |